AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03143530 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Pectoralis block
Description: Pectoralis block involving injection near the coracoid process in the fascial planes between both the pectoralis major and minor muscles (pecs I), and the fascial plane between the pectoralis minor and serratus anterior muscles (pecs II).
Study NCT03143530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline injection
Description: Pectoralis block involving injection of normal saline 30ml near the coracoid process in the fascial planes between both the pectoralis major and minor muscles (pecs I), and the fascial plane between the pectoralis minor and serratus anterior
Study NCT03143530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine Injection
Description: Pectoralis block involving injection of ropivacaine injection 30ml of 0,25% (75 mg) near the coracoid process in the fascial planes between both the pectoralis major and minor muscles (pecs I), and the fascial plane between the pectoralis minor and serratus anterior
Study NCT01929590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-3350 group 2
Description: split-dose (PEG-3350; 2 L the day before 17:00-19:00 h and 2 L same day of the procedure 06:00-08:00 am)
Study NCT01929590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-3350 group 1
Description: PEG-3350; PEG-4 L the day previous of the study, starting at 17:00 and finishing at 21:00 h
Study NCT01929590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-3350 group 3
Description: low-volume 2 L PEG-solution (same day of the procedure 06:00-08:00 am)
Study NCT00687401 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab 5 mg/kg of body weight administered as an infusion at Weeks 0, 2, 6 (induction phase), and 14 (maintenance phase).
Study NCT03178435 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Measures to prevent AKI among critically ill patients
Description: 1. Meticulous optimization of the fluid balance~2. Avoidance of nephrotoxic medications where possible~3. Optimisation of the hemodynamic status~4. Avoidance of blood transfusion unless marked acute blood loss or symptomatic anemia~5. Optimization of the underlying medical condition~6. Seek expert renal advise when necessary
Study NCT03703778 — intervention group
Intervention type: PROCEDURE
Intervention: Androgen deprivation therapy - bilateral orchidectomy
Description: Androgen deprivation therapy (ADT) is a kind of hormone therapy for prostate cancer. The goal is to reduce levels of male hormones, called androgens, in the body, or to stop them from affecting prostate cancer cells. It can be surgical, i.e. bilateral orchidectomy, or medical, i.e. GnRH agonist or GnRH antagonist.
Study NCT03703778 — intervention group
Intervention type: DRUG
Intervention: Androgen deprivation therapy - GnRH agonist
Description: Androgen deprivation therapy (ADT) is a kind of hormone therapy for prostate cancer. The goal is to reduce levels of male hormones, called androgens, in the body, or to stop them from affecting prostate cancer cells. It can be surgical, i.e. bilateral orchidectomy, or medical, i.e. GnRH agonist or GnRH antagonist.
Study NCT03703778 — intervention group
Intervention type: DRUG
Intervention: Androgen deprivation therapy - GnRH antagonist
Description: Androgen deprivation therapy (ADT) is a kind of hormone therapy for prostate cancer. The goal is to reduce levels of male hormones, called androgens, in the body, or to stop them from affecting prostate cancer cells. It can be surgical, i.e. bilateral orchidectomy, or medical, i.e. GnRH agonist or GnRH antagonist.
Study NCT02230566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UX003
Description: UX003 is a sterile concentrate formulation of rhGUS for intravenous infusion
Study NCT01981473 — intervention group
Intervention type: OTHER
Intervention: no intervention
Study NCT02230566 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo consisting of the UX003 formulation buffer (without rhGUS)
Study NCT03368339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PR013 (0.045%)
Description: PR013 topical Ophthalmic Drops (0.045%)
Study NCT03368339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PR013 (0.06%)
Description: PR013 topical Ophthalmic Drops (0.06%)
Study NCT03368339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle
Study NCT00809601 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insertion of a specific type of ventilation tube through the tympanic membrane
Description: The ventilation tubes are tested using one type in one ear and another type as an active comparator in the other ear.~The investigators will test in total 4 different kinds of tubes. Four different combinations of tubes will be tested.~The first combination will test:~Shepard tube (double flanged, Fluoroplastic) vs Donaldson tube (double flanged, silicone)~The second combination will test:~Straight tube (single flanged, Fluoroplastic) vs Armstrong (single flanged, silicone)~The third combination will test:~Armstrong (single flanged, silicone) vs Donaldson tube (double flanged, silicone)~The fourth combination will test:~Straight tube (single flanged, Fluoroplastic) vs Shepard tube (double flanged, Fluoroplastic)
Study NCT02436590 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthofix Physio-Stim Model 3315OA
Description: Active device emits PEMF signal; placebo/control device does not emit PEMF signal
Study NCT02436590 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Orthofix Physio-Stim Model 3315OA
Description: Active device emits PEMF signal; placebo/control device does not emit PEMF signal
Study NCT01119599 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3-D conformal radiation therapy
Study NCT01119599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma-Secretase Inhibitor RO4929097
Description: Given PO
Study NCT04183114 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles-Rubella vaccine Bio Farma
Description: MR vaccine produced by Bio Frama with 3 consecutive batches
Study NCT01119599 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT04183114 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MR Vaccine SII
Description: MR Vaccine produced by SII (Already registered in Indonesia)
Study NCT03798613 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Apple Watch 4 Series Device
Description: tracings from the apple watch 4 series watch
Study NCT03798613 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Telemetry Monitor
Description: tracings from the continuous telemetry monitor
Study NCT03306966 — intervention group
Intervention type: DEVICE
Intervention: Endoscopic Linear Cutter Stapler and Reloads (Frankenman)
Description: The Single Use Endoscopic Linear Cutter Stapler and Reloads from Frankenman received CE-mark in April 2013. It is used to staple and simultaneously divide tissue from the central line.
Study NCT00184223 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: 2 sessions of 45 minutes each with manual guided motivational interviewing delivered individually by a trained therapist.
Study NCT00184223 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Treatment as usual is individualized according to the clinical condition of the patients during the stay and in accordance with general national and international medical standards. It includes detoxification, pharmacotherapy, and general psychotherapy. Also, treatment is given for any coexisting non-substance-related disorder, including psychiatric disorders.
Study NCT00184223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Treatment as usual is individualized according to the clinical condition of the patients during the stay and in accordance with general national and international medical standards. It includes detoxification, pharmacotherapy, and general psychotherapy. Also, treatment is given for any coexisting non-substance-related disorder, including psychiatric disorders.
Study NCT01655758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% timolol
Study NCT01655758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: timolol-dorzolamide fixed combination
Study NCT01655758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost
Study NCT01655758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost
Study NCT01119599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01655758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoprost
Study NCT01119599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01119599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT01119599 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT03246776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Halometasone Triclosan
Description: Halometasone Triclosan . The study product will be applied topically twice a day (morning and evening) for 14 days of treatment
Study NCT01066520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traumeel S ointment
Description: 2 g, 3 times daily topical during 14 days
Study NCT01066520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traumeel S gel
Description: 2 g, 3 times daily topical during 14 days
Study NCT01066520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac gel
Description: 2 g, 3 times daily topical during 14 days
Study NCT00370682 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-DEN F17
Description: A single dose of 0.5 mL of the dengue vaccine was injected subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm at Day 0 and at 6 months.
Study NCT00370682 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-DEN F-19
Description: A single dose of 0.5 mL of the dengue vaccine was injected subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm at Day 0 and at 6 months.
Study NCT00370682 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: A single dose of 0.5 mL of the placebo sterile solution of buffer identical in appearance to vaccine)was injected subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm at Day 0 and at 6 months.
Study NCT03323073 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resting state fMRI
Description: One single fMRI which is used to characterize a uni or a bipolar major depressive episode (MDE).
Study NCT03323073 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Resting state fMRI
Description: One single fMRI which is used to characterize a uni or a bipolar major depressive episode (MDE).
Study NCT03904212 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adipose tissue injection
Description: Injection with freshly harvested autologous adipose tissue
Study NCT03904212 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: injection with saline
Study NCT04539600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab is a type of anti-PD-1 antibody that could enhance the immune system of the patient to fight cancer.
Study NCT02124733 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aminolevulinic acid based photodynamic therapy
Description: The PDT treatments will be done in two stages. ALA (Levulan® Kerastick™) will be applied to the entire treatment area, and then the longer light exposure (lasting up to 1 hr) will be performed on one-half of the treatment area (Side A). After that, a shorter (16 min 40 sec) light exposure will be done on the other half (Side B).
Study NCT00495729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-649868
Description: Subjects will receive SB-649868 5 mg, 25 mg tablets orally 1 hour prior to simvastatin administration.
Study NCT00495729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive matching placebo tablets to SB-649868 orally 1 hour prior to simvastatin administration.
Study NCT00495729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Subjects will receive Simvastatin 10 mg tablets orally.
Study NCT01983228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Condition
Description: Intervention participants will complete 6 sessions of telephone coaching over a 10-12 week period, using a patient workbook with visual aids (e.g., diagram of the pain/inactivity cycle) and worksheets that they will complete during the counseling sessions. Participants are expected to receive approximately 180 minutes of total therapist time during the study.
Study NCT01622621 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sublobar Resection
Description: Undergo surgery which removes a sublobar resection of the lung
Study NCT01622621 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: 54 Gy in 3 fractions
Study NCT00531258 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: Bilateral rTMS
Study NCT00531258 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham rTMS
Description: sham rTMS
Study NCT00646685 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgical technique: duct-to-duct biliary reconstruction
Description: surgical reconstruction
Study NCT00646685 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgical technique: roux-en-y biliary reconstruction
Description: surgical reconstruction
Study NCT02336607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Felodipine tablet (Plendil) alone
Description: Felodipine sustained release tablet single drug therapy (1st week- 2nd week) Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks. If blood pressure is controlled after 2 weeks, then the subjects will continue the treatment until the end of primary therapy stage (14th week).
Study NCT02336607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Felodipine tablet (Plendil)+Hydrochlorothiazide
Description: Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks.~If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with hydrochlorothiazide 12.5mg, once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled.
Study NCT02336607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Felodipine tablet (Plendil)+Metoprolol tablet (Betaloc ZOK)
Description: Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks.~If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with metoprolol succinate prolonged-release tablet (Betaloc ZOK) 47.5mg , once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled.
Study NCT02336607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Felodipine tablets (Plendil)+Lisinopril (Zestril)
Description: Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks.~If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with Lisinopril (Zestril) 10mg, once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled.
Study NCT01180335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: 4 cycles FEC followed by 4 cycles docetaxel
Study NCT01180335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genomic driven chemotherapy
Description: High DLD30 receive 3 months weekly paclitaxel followed by 4 FEC, patients with high TOP2A receive 4FEC then 4 docetaxel, patients with low DLD30 and low TOP2A are treated with 6 cycles of docetaxel-capecitabine.
Study NCT04139226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-11050
Description: CC-11050
Study NCT02643459 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: suPAR measurement
Description: The biomarker suPAR will be measured on all patients included in the study. Before the study period the doctors will receive information on suPAR. We want to study if the information provided by suPAR is useful in emergency medicine. Interventions depends on the clinical issue, as suPAR is an unspecific marker of disease. Usually a elevated suPAR level could result in more investigation e.g. diagnostic procedures or follow up, while a low suPAR could result in faster discharge.
Study NCT01167803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: Patients undergo anesthesia using remifentanil associated with desflurane
Study NCT01167803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon
Description: Patients undergo anesthesia using remifentanil associated with xenon
Study NCT00721396 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ
Study NCT00721396 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: combined diphtheria,tetanus,pertussis+polio+Hepatitis B+Haemophilus influenzae B vaccine
Study NCT00721396 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: combined diphtheria,tetanus,pertussis+polio+Hepatitis B+Haemophilus influenzae B vaccine
Study NCT00721396 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine
Study NCT00721396 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal vaccine
Study NCT00371592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir
Description: 800 mg tablet taken orally twice daily
Study NCT00371592 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acyclovir placebo
Description: 800 mg placebo tablet taken orally twice daily
Study NCT03746626 — intervention group
Intervention type: BEHAVIORAL
Intervention: Chaplain visit
Description: The patients will all see a chaplain routinely during 8-week stay according to their personal preference. The chaplain records the 'depth' and frequency of these encounters.
Study NCT01809821 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Sleep Education
Study NCT00757237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aztreonam for Inhalation Solution (AZLI)
Description: Aztreonam for inhalation solution (75 mg) was administered 3 times a day (TID) for 28 days for each treatment cycle via the PARI eFlow electronic nebulizer.
Study NCT00757237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin Inhalation Solution (TIS)
Description: Tobramycin inhalation solution (300 mg) was administered 2 times a day (BID) for 28 days for each treatment cycle via the PARI LC Plus nebulizer with compressor or via another nebulizer compatible with country-specified labeling.
Study NCT03067428 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: Participants will adhere to a fructose restricted diet for a period of six weeks (\<7.5 grams/meal and/or \<10 grams/day; ad-libitum intake). In addition, the amount of fructose that will be restricted - which is based on the average individual fructose intake assessed prior to randomization - will be supplemented as glucose powder three times daily during the meal.
Study NCT03067428 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fructose
Description: Participants will adhere to a fructose restricted diet for a period of six weeks (\<7.5 grams/meal and/or \<10 grams/day; ad-libitum intake). In addition, the amount of fructose that will be restricted - which is based on the average individual fructose intake assessed prior to randomization - will be supplemented as fructose powder three times daily during the meal.